When patients with MASLD have major metabolic improvement on modern anti-obesity/antidiabetic therapies, how do you interpret changes in NITs over time—do you re-stage prognosis based on updated values, and what magnitude/duration of change is sufficient to de-escalate or escalate liver- specific surveillance?